Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.

Trial Profile

A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2018

At a glance

  • Drugs PF-06863135 (Primary) ; PF-06863135 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 04 Dec 2018 Results (n=5) presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 24 Sep 2018 Planned End Date changed from 14 Feb 2022 to 13 Feb 2022.
    • 24 Aug 2018 Planned End Date changed from 4 May 2022 to 14 Feb 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top